Literature DB >> 1963453

Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region.

H Okamoto1, S Okada, Y Sugiyama, T Tanaka, Y Sugai, Y Akahane, A Machida, S Mishiro, H Yoshizawa, Y Miyakawa.   

Abstract

The 5'-noncoding region of hepatitis C virus (HCV) genomes is highly conserved. A two-stage polymerase chain reaction (PCR), involving two pairs of primers deduced from the 5'-noncoding region of the HCV genome, was developed for a sensitive and specific detection of HCV RNA. The first stage of PCR was performed for 35 cycles with primers capable of multiplying fragments of 221 base pairs. PCR products in samples negative for HCV RNA were subjected to the second stage of PCR for 30 cycles with primers located internal to those employed in the first stage of PCR. The two-stage PCR detected up to 10 chimpanzee infectious doses/ml of HCV, and HCV RNA in 11 (92%) of 12 sera from patients with chronic non-A, non-B hepatitis without detectable antibodies to HCV by a commercial assay kit. Primers from the 5'-noncoding region of the HCV genome would be suitable for detecting HCV RNA by PCR, since the other regions of the HCV genome diverge extensively in sequence because of its nature as an RNA virus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1963453

Source DB:  PubMed          Journal:  Jpn J Exp Med        ISSN: 0021-5031


  99 in total

1.  Quantitative HCV RNA and effect of interferon therapy in chronic hepatitis C.

Authors:  G Yamada; M Takahashi; T Tsuji; H Yoshizawa; H Okamoto
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

2.  Effects of anticoagulants and storage of blood samples on efficacy of the polymerase chain reaction assay for hepatitis C virus.

Authors:  J T Wang; T H Wang; J C Sheu; S M Lin; J T Lin; D S Chen
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

3.  Activation of hepatitis C virus following immunosuppressive treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Kanamori; F Kodama; H Okamoto
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

4.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; K Yamamoto; S Yotsumoto
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

5.  Recent advances in laboratory diagnosis of hepatitis C virus infection.

Authors:  R Chaudhary
Journal:  Can J Infect Dis       Date:  1994-11

6.  Detection of antibodies to hepatitis C virus (HCV) structural proteins in anti-HCV-positive sera by an enzyme-linked immunosorbent assay using synthetic peptides as antigens.

Authors:  C Ishida; K Matsumoto; K Fukada; K Matsushita; H Shiraki; Y Maeda
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

7.  Hepatitis C markers in hemodialysis patients.

Authors:  C S Huang; M S Ho; C S Yang; C L Lee; C A Tan
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

8.  Prevalence and significance of hepatitis C virus (HCV) viremia in HCV antibody-positive subjects from various populations.

Authors:  M François; F Dubois; D Brand; Y Bacq; C Guerois; C Mouchet; J Tichet; A Goudeau; F Barin
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

9.  Immunoperoxidase staining of hepatitis C virus in formalin-fixed, paraffin-embedded needle liver biopsies.

Authors:  T Uchida; T Shikata; E Tanaka; K Kiyosawa
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

10.  Importance of adequate immunosuppressive therapy for the recovery of patients with "life-threatening" severe exacerbation of chronic hepatitis B.

Authors:  Keiichi Fujiwara; Osamu Yokosuka; Hiroshige Kojima; Tatsuo Kanda; Hiromitsu Saisho; Hiroyuki Hirasawa; Hiroshi Suzuki
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.